Circulating miRNAs as biomarkers for the diagnosis in patients with melanoma: systematic review and meta-analysis

9Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

Abstract

Objective: Melanoma is the most aggressive and deadly form of skin cancer, especially at later stages. There is currently no excellent diagnostic test established for the diagnosis of melanoma; however, circulating microRNAs (miRNAs) have shown some promise. We seek to conduct a systematic review and meta-analysis to establish the clinical utility of circulating miRNAs in diagnosing melanoma. Methods: PubMed, Wiley, and Web of Science were searched for studies that determined miRNA sensitivity and specificity in patients with melanoma. The included studies were assessed in Stata, and the sensitivity, specificity, summary receiver operating characteristic (SROC), positive likelihood ratio, negative likelihood ratio, and the area under the SROC curve (AUC) were calculated. Results: 9 studies with 898 melanoma patients were included in the meta-analysis. The circulating miRNAs showed high diagnostic accuracy with a sensitivity of 0.89 (p < 0.001), specificity of 0.85 (p < 0.001), diagnostic odds ratio of 45, and an area under the curve of 0.93. Conclusion: Circulating miRNAs have shown a high diagnostic power in detecting melanoma.

Cite

CITATION STYLE

APA

Jones, N., & Nonaka, T. (2024, February 14). Circulating miRNAs as biomarkers for the diagnosis in patients with melanoma: systematic review and meta-analysis. Frontiers in Genetics. Frontiers Media SA. https://doi.org/10.3389/fgene.2024.1339357

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free